Patents Examined by Mojdeh Bahar
  • Patent number: 6660750
    Abstract: Disclosed is the unexpected discovery that flavopiridol binds tightly to the transcription elongation factor, P-TEFb and dramatically inhibits its activity. As P-TEFb is required for HIV propagation and replication, this invention provides new methods, compositions and kits for the effective treatment of HIV infections and AIDS using flavopiridol, both alone and combination with other therapies.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: December 9, 2003
    Assignees: University of Iowa Research Foundation, The United States of America as represented by the Department of Health and Human Services
    Inventors: David H. Price, Adrian M. Senderowicz
  • Patent number: 6656973
    Abstract: Provided are the compound (E)-4-carboxystyryl-4-chlorobenzyl sulfone, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 27, 2002
    Date of Patent: December 2, 2003
    Assignee: Temple University - Of the Commonwealth System of Higher Education
    Inventors: Stephen C. Cosenza, M. V. Ramana Reddy, E. Premkumar Reddy
  • Patent number: 6653298
    Abstract: Disclosed and claimed are methods for oral contraception, or a hormone replacement therapy, or for treating breast cancer, in a patient in need thereof involving administering to the patient, at a dosage of no greater than 200 &mgr;g/day per 70 kg subject, a compound having Formula (I): wherein X in combination with K form a steroidal ring and R5 is a sulphamate group that has of the formula: wherein each of R1 and R2 is H.
    Type: Grant
    Filed: January 5, 2001
    Date of Patent: November 25, 2003
    Assignees: Sterix Limited, Schering AG
    Inventors: Barry Victor Lloyd Potter, Michael John Reed, Walter Elger, Gudrun Roddersen, Heinrich-Thomas Proske
  • Patent number: 6632827
    Abstract: Compositions and methods utilizing the optically pure (+) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders of the central nervous system. The compound, (+) norcisapride, has also been found to be a potent antiemetic agent. Finally, the (+) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: October 14, 2003
    Assignee: Sepracor Inc.
    Inventors: John R. McCullough, Thomas P. Jerussi
  • Patent number: 6627649
    Abstract: The invention relates to pharmaceutical compositions containing (2S)-1-{(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzenesulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl}pyrrolidine-2-carboxamide, a selective V1a arginine vasopressin receptor antagonist, in combination with the equatorial isomer of 1-{4-(N-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl}-5-ethoxy-3-spiro{4-(2-morpholinoethyloxy)cyclohexane}indol-2-one or one of its salts, a selective V2 arginine vasopressin receptor antagonist. The invention relates to the use of such compositions for the production of medicines designed to treat all diseases for which either arginine vasopressin or the V2 receptors are implicated or to treat all diseases related to a water overlead.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: September 30, 2003
    Assignee: Sanofi-Synthelabo
    Inventors: Colette Lacour, Dino Nisato
  • Patent number: 6627655
    Abstract: Novel spermicidal compounds which are organometallic cyclopentadienyl metal complexes, particularly vanadium IV complexes, including their corresponding therapeutic compositions are described.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: September 30, 2003
    Assignee: Parker Hughes Institute
    Inventors: Osmond D'Cruz, Phalguni Ghosh, Fatih M. Uckun
  • Patent number: 6613795
    Abstract: Disclosed are enantiomerically pure cyclic aminoalcohol esters of arylcycloalkylhydroxycarboxylic acids with at least 90% enantiomeric excess of the (3R,2′R), (3S,2′R), (3R,2′S), or (3S,2′S) configured enantiomer.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: September 2, 2003
    Inventors: Christian Noe, Ernst Mutschler, G√ľnter Lambrecht, Michael Elgert, Sittah Czeche, Magali Waelbroeck
  • Patent number: 6569864
    Abstract: Compositions and kits comprising acyclovir and fusaric acid are provided.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: May 27, 2003
    Assignee: Novactyl, Inc.
    Inventors: Michael G. Douglas, Avinash N. Amin
  • Patent number: 6552048
    Abstract: Sulfonylcarboxamide derivatives of formula I, their physiologically acceptable salts and/or physiologically functional derivatives, methods of making these compounds, their use for preparing medicines for the prevention and treatment of hyperlipidemia and arteriosclerotic disorders. The compounds of formula I have the following structure: in which the radicals are as defined and their physiologically acceptable salts and physiologically functional derivatives are described.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: April 22, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Reinhard Kirsch, Hans-Ludwig Schaefer, Eugen Falk, Horst Hemmerle
  • Patent number: 6534534
    Abstract: The present application relates to a method of treating atherosclerosis by administering to a patient a compound of formula: and/or salts thereof with pharmaceutically acceptable organic or inorganic bases.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: March 18, 2003
    Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
    Inventors: Angelo Guglielmotti, Alberto Mantovani
  • Patent number: 6528037
    Abstract: A method for determining whether a compound is an insulin receptor kinase activator.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: March 4, 2003
    Assignee: Telik, Inc.
    Inventors: Prasad V. V. S. V. Manchem, Robert T. Lum, Steven R. Schow
  • Patent number: 6506799
    Abstract: The present invention relates to methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension comprising administering a composition comprising an ether compound.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: January 14, 2003
    Assignee: Esperion Therapeutics, Inc.
    Inventor: Jean-Louis Henri Dasseux
  • Patent number: 6503939
    Abstract: This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds that are antagonists of the progesterone receptor having the structure: wherein: R1 and R2 are (i) H, OH, OAc, alkylaryl, alkylheteroaryl, 1-propynyl, 3-propynyl, and optionally substituted alkyl, O(alkyl), aryl, or heteroaryl; (ii) a ring or (iii) a double bond; R3 is H, OH, NH2, CORA; or optionally substituted alkenyl or alkynyl; RA=H or optionally substituted alkyl, alkoxy, or aminoalkyl groups; R4=H, halo, CN, NH2, or optionally substituted alkyl, alkoxy, or aminoalkyl; R5 is a benzene ring; heterocyclic ring; an indole or benzothiophene; or pharmaceutically acceptable salt. R6 and R7 are H, methyl, ethyl, propyl, butyl, iso-propyl, isobutyl, cyclohexyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: January 7, 2003
    Assignees: Wyeth, Ligand Pharmaceuticals, Inc.
    Inventors: Gary S. Grubb, John W. Ullrich, Andrew Fensome, Jay E. Wrobel, James P. Edwards, Todd K. Jones, Christopher M. Tegley, Lin Zhi
  • Patent number: 6500860
    Abstract: Novel spermicidal compounds which are organometallic cyclopentadienyl metal complexes, particularly vanadium IV complexes, are described including corresponding contraceptive and therapeutic compositions and method for providing contraception and selective killing of testicular germ cells. Included among the vanadium complexes are bis(methyl cyclopentadienyl)vanadium dichloride, vanadocene di-pseudohalides, and others. Most active found was vanadocene diselenocyanate.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: December 31, 2002
    Assignee: Parker Hughes Institute
    Inventors: Osmond D'Cruz, Phalguni Ghosh, Fatih M. Uckun
  • Patent number: 6492407
    Abstract: A method for treating a neurodegenerative disease or cerebral ischemia arising from conditions selected from the group consisting of Status epilepticus, hypoglycaemia, hypoxia, anoxia, brain trauma, brain oedema, amyotropic lateral sclerosis, Huntington's disease, Alzheimer's disease, hypotonia, cardiac infarction, brain pressure (elevated intracranial pressure), ischaemic and haemorrhagic stroke, global cerebral ischaemia with heart stoppage, diabetic polyneuropathy, tinnitus, perinatal asphyxia, psychosis, schizophrenia, depression, and Parkinson's disease, the method of treatment comprising administering to a host in need of such treatment a therapeutic amount of a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions containing a compound of formula (I).
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: December 10, 2002
    Assignee: Boehringer Imgelheim Pharma KG
    Inventors: Michael Brenner, Wolf-Dietrich Bechtel, Rainer Palluk, Marion Wienrich, Thomas Weiser
  • Patent number: 6492428
    Abstract: There are disclosed methods of use and pharmaceutical compositions for two related genera of low molecular weight compounds comprising optionally substituted iminoquinone or orthoquinone ring systems. The compounds have MIF (macrophage migration inhibitory factor) antagonist activity and find utility as such. For example, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatiod arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, EAE, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).
    Type: Grant
    Filed: July 26, 2000
    Date of Patent: December 10, 2002
    Assignee: The Picower Institute for Medical Research
    Inventors: Yousef Al-Abed, Richard J. Bucala, Robert A. Mitchell, Peter Senter
  • Patent number: 6486181
    Abstract: The present invention relates to a method for inhibiting the etiology of disease in patients having a disease state caused by an excess of 12-lipoxygenase or its products. In particular, the invention provides for administration of a human leukocyte 12-lipoxygenase pathway inhibitor to inhibit disease etiology, to inhibit the proliferation of breast cancer and to increase insulin receptor phosphorylation in a patient having Type II diabetics.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: November 26, 2002
    Assignee: City of Hope
    Inventors: Jerry L. Nadler, Rama Natarajan
  • Patent number: 6485727
    Abstract: To prevent and/or alleviate the discomfort of mild-to-moderate chronic venous insufficiency of the lower extremities, the dietary supplement should be taken in dosages corresponding to 80-1000 mg of extract, preferably 300-800 mg, in particular 350-750 mg daily. The total amount of extract may be divided up in 1 to 3 capsules or tablets a day (or an equivalent dose by means of a liquid form). The daily dose should be taken at once, preferably in the morning.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: November 26, 2002
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Anke Esperester, Hans W. Frey, Jean-Michel Vix
  • Patent number: 6451807
    Abstract: The present invention relates to highly selective phosphodiesterase (PDE) enzyme inhibitors and to their use in methods of treating sexual dysfunction in individuals suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: September 17, 2002
    Assignee: Lilly Icos, LLC.
    Inventors: Jeffrey T. Emmick, Kenneth M. Ferguson, William E. Pullman, John S. Whitaker
  • Patent number: 6436988
    Abstract: The present application relates to the use of 3-(2,4,6-trimethylphenyl) -4-neopentylcarbonyloxy-5,5-tetramethylene-&Dgr;3-dihydrofuran-2-one for controlling insects of the family Aleurodidae (white fly).
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: August 20, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventor: Ulrike Wachendorff-Neumann